Back to all assets

Edwards Lifesciences EW

equity

Price History

$1.12$43.93$86.74$129.55
2000-03 · DCA start$1.13

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-51.3%-34.2%-17.1%0.0%
2000-032026-08 · -28.2%

Worst drawdown: −51%, peaking Dec 2021 and bottoming Jul 2024 — still unrecovered after 56 months.

DCA Backtest

Invested
$31,800
Value today
$462,144
Return
+1353.3%
Months invested
318

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $46,250 today, so the real (inflation-adjusted) return is +899.2%.

Lump sum instead — $31,800 all at once in Mar 2000: $2,618,093 (+8133.0%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Dec 2021): $6,475 on $5,700 invested (+13.6%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2000-03: +1353.3%

About Edwards Lifesciences

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. (Wikipedia)

It's a listed company categorised under health care and health care equipment, with a market cap of about $53.6B.

It rates Medium-High Risk at 2.4/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: earnings quality (5.0/5) and sector / regulatory (3.0/5).

Scoring well: leverage / financial at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.4/5)80% rated

How these ratings work

Market / Volatility2.7/5 · weight 20%
  • Annualised volatility (3yr)3/530.8
  • Max drawdown from ATH3/551.3
  • Beta vs S&P 5002/50.59
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5443.1m
  • Float % of shares outstandingnot yet researched
Leverage / Financial1.0/5 · weight 20%
  • Debt / equity1/50.06
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality5.0/5 · weight 15%
  • 3yr EPS volatility5/5196
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.